title: Adolescent Asthma Pharmacotherapy in a State of Flux.
abstract: Recently, the United States Food and Drug Administration (FDA) elected not to approve a once-daily inhaled corticosteroid/long-acting β2 agonist combination product in 12-17-year-old patients due to lack of sufficient data, despite approval of previous combination products with similar levels of supporting evidence. As the FDA's stance toward adolescent data is changing, the opportunity to learn about their response to asthma medication has now arisen. A review of the relevant issues pertinent to pharmacotherapy of asthma in the 12-17-year-old population is discussed in this review.
authors.affiliation: Department of Pediatrics, School of Medicine, University of New Mexico , Alburquerque, New Mexico.
authors.forename: Hengameh
authors.initials: H
authors.lastname: Raissy
authors.affiliation: Biomedical Research Department, Nemours Children's Clinic , Jacksonville, Florida.
authors.forename: Kathryn
authors.initials: K
authors.lastname: Blake